Enzalutamide + Radium-223 Shows Delayed Survival Gains in Metastatic CRPC: Key PEACE-3 Trial Insights
At the American Urological Association (AUA) 2026 conference, a reconstructed individual patient data (IPD) analysis of the PEACE-3 trial revealed that AstraZeneca (NASDAQ: AZN)‘s combination therapy of enzalutamide (Xtandi) and ... Read More